Evidence map›Paper›PMID 31970398›Full record

ArticleThe Journal of infectious diseases2020

Evaluation of Genotypic Antiviral Resistance Testing as an Alternative to Phenotypic Testing in a Patient with DOCK8 Deficiency and Severe HSV-1 Disease.

Amanda M Casto, Sean C Stout, Rangaraj Selvarangan, Alexandra F Freeman, Brandon D Newell, Erin D Stahl, Atif A Ahmed, Alexander L Greninger, Dwight E Yin

Open access · greenAbstract readCase ReportsEvaluation Study
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Practical updates in clinical antiviral resistance testing.Journal of clinical microbiology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Amanda M CastoDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Sean C StoutDepartment of Pediatrics, Children's Mercy, Kansas City, Missouri, USA.
Rangaraj SelvaranganDepartment of Pathology and Laboratory Medicine, Children's Mercy, Kansas City, Missouri, USA.
Alexandra F FreemanLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Brandon D NewellSchool of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Erin D StahlSchool of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Atif A AhmedDepartment of Pathology and Laboratory Medicine, Children's Mercy, Kansas City, Missouri, USA.
Alexander L GreningerDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Dwight E YinSchool of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Children's Mercy Hospital · USUniversity of Washington · USNational Institutes of Health · US

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Training Program in Infectious Diseases in the Immunocompromised HostT32AI118690 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2016 to 2025
$4.0M
NIAID NIH HHS T32 AI007140NIAID NIH HHS T32 AI118690
6 · The paper itself

Abstract

Antiviral resistance frequently complicates the treatment of herpes simplex virus (HSV) infections in immunocompromised patients. Here we present the case of an adolescent boy with dedicator of cytokinesis 8 (DOCK8) deficiency, who experienced recurrent infections with resistant HSV-1. We used both phenotypic and genotypic methodologies to characterize the resistance profile of HSV-1 in the patient and conclude that genotypic testing outperformed phenotypic testing. We also present the first analysis of intrahost HSV-1 evolution in an immunocompromised patient. While HSV-1 can remain static in an immunocompetent individual for decades, the virus from this patient rapidly acquired genetic changes throughout its genome. Finally, we document a likely case of transmitted resistance in HSV-1 between the patient and his brother, who also has DOCK8 deficiency. This event demonstrates that resistant HSV-1 is transmissible among immunocompromised persons.

Indexed as

AdolescentAntiviral AgentsDNA, ViralDrug Resistance, ViralGenotyping TechniquesGuanine Nucleotide Exchange FactorsHerpes SimplexHerpesvirus 1, HumanHumansImmunocompromised HostMaleMicrobial Sensitivity TestsPolymorphism, Single NucleotideSeverity of Illness IndexSkinAntiviral AgentsDNA, ViralDOCK8 protein, humanGuanine Nucleotide Exchange FactorsDOCK8 deficiencygenotypic antiviral resistanceHSV-1immunodeficiencyintrahost evolutionphenotypic antiviral resistancetransmitted resistance

Identifiers

PMID31970398
PMCPMC7289554
OpenAlexW3002158894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.